

Joseph Meletiadis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6639524/publications.pdf>

Version: 2024-02-01

154
papers

8,593
citations

76326

40
h-index

48315

88
g-index

156
all docs

156
docs citations

156
times ranked

7568
citing authors

#	ARTICLE	IF	CITATIONS
1	Comment on: Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1209-1210.	3.0	6
2	Oral fosfomycin activity against <i>Klebsiella pneumoniae</i> in a dynamic bladder infection <i>in vitro</i> model. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1324-1333.	3.0	6
3	OUP accepted manuscript. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, , .	3.0	1
4	Expected phenotypes and Expert Rules are Important Complements to Antimicrobial Susceptibility Testing. <i>Clinical Microbiology and Infection</i> , 2022, , .	6.0	0
5	Early phenotypic detection of fluconazole- and anidulafungin-resistant <i>Candida glabrata</i> isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1655-1661.	3.0	2
6	Fungemia due to <i>Moesziomyces aphidis</i> (<i>Pseudozyma aphidis</i>) in a premature neonate. Challenges in species identification and antifungal susceptibility testing of rare yeasts. <i>Journal De Mycologie Medicale</i> , 2022, 32, 101258.	1.5	2
7	Evaluation of the Dynamikr® Fungus (1 ³)- β -D-Glucan Assay for the Diagnosis of Invasive Aspergillosis in High-Risk Patients with Hematologic Malignancies. <i>Infectious Diseases and Therapy</i> , 2022, , .	4.0	3
8	Epidemiology of Candidemia and Fluconazole Resistance in an ICU before and during the COVID-19 Pandemic Era. <i>Antibiotics</i> , 2022, 11, 771.	3.7	23
9	Population pharmacokinetics of anidulafungin in ICU patients assessing inter- and intrasubject variability. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1024-1032.	2.4	7
10	Oral ribavirin is a highly effective treatment for lower respiratory tract infections due to respiratory syncytial virus or parainfluenza after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 511-513.	2.4	3
11	How to: perform antifungal susceptibility testing of microconidia-forming dermatophytes following the new reference EUCAST method E.Def 11.0, exemplified by Trichophyton. <i>Clinical Microbiology and Infection</i> , 2021, 27, 55-60.	6.0	51
12	Characterization and outcome of invasive infections due to <i>Paecilomyces variotii</i> : analysis of patients from the FungiScope® registry and literature reports. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 765-774.	3.0	22
13	Antimicrobial pharmacokinetics and preclinical <i>in vitro</i> models to support optimized treatment approaches for uncomplicated lower urinary tract infections. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 271-295.	4.4	5
14	<i>In-vitro</i> pharmacokinetic/pharmacodynamic model data suggest a potential role of new formulations of posaconazole against <i>Candida krusei</i> but not <i>Candida glabrata</i> infections. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106291.	2.5	6
15	Comparative Pharmacodynamics of Echinocandins against <i>Aspergillus fumigatus</i> Using an <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic Model That Correlates with Clinical Response to Caspofungin Therapy: Is There a Place for Dose Optimization?. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	6
16	Activity of Cefepime in Combination with the Novel β -Lactamase Inhibitor Taniborbactam (VNRX-5133) against Extended-Spectrum- β -Lactamase-Producing Isolates in <i>In Vitro</i> Checkerboard Assays. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	15
17	The Role of New Posaconazole Formulations in the Treatment of <i>Candida albicans</i> Infections: Data from an <i>In Vitro</i> Pharmacokinetic-Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	6
18	Performance, Correlation and Kinetic Profile of Circulating Serum Fungal Biomarkers of Invasive Aspergillosis in High-Risk Patients with Hematologic Malignancies. <i>Journal of Fungi (Basel)</i> , 2021, 6, 1011-1020.	0.0	0

#	ARTICLE	IF	CITATIONS
19	Molecular Epidemiology and Antifungal Susceptibility of Trichophyton Isolates in Greece: Emergence of Terbinafine-Resistant Trichophyton mentagrophytes Type VIII Locally and Globally. <i>Journal of Fungi</i> (Basel, Switzerland), 2021, 7, 419.	3.5	46
20	Epidemiology and Incidence of COVID-19-Associated Pulmonary Aspergillosis (CAPA) in a Greek Tertiary Care Academic Reference Hospital. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1779-1792.	4.0	17
21	Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e375-e386.	9.1	80
22	Pharmacokinetic/pharmacodynamic analysis of oral fosfomycin against Enterobacterales, <i>Pseudomonas aeruginosa</i> and <i>Enterococcus</i> spp. in an in vitro bladder infection model: impact on clinical breakpoints. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3201-3211.	3.0	3
23	In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against <i>Klebsiella pneumoniae</i> and cefepime against <i>Pseudomonas aeruginosa</i> metallo-beta-lactamase-producing clinical isolates. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106440.	2.5	11
24	A Prospective Multicenter Cohort Surveillance Study of Invasive Aspergillosis in Patients with Hematologic Malignancies in Greece: Impact of the Revised EORTC/MSGERC 2020 Criteria. <i>Journal of Fungi</i> (Basel, Switzerland), 2021, 7, 27.	3.5	10
25	MixInYeast: A Multicenter Study on Mixed Yeast Infections. <i>Journal of Fungi</i> (Basel, Switzerland), 2021, 7, 13.	3.5	14
26	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). <i>Journal of Hematology and Oncology</i> , 2021, 14, 168.	17.0	189
27	Genetic diversity and antifungal susceptibility patterns of <i>Aspergillus nidulans</i> complex obtained from clinical and environmental sources. <i>Mycoses</i> , 2020, 63, 78-88.	4.0	16
28	Impact of bacterial species and baseline resistance on fosfomycin efficacy in urinary tract infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 988-996.	3.0	13
29	Epidemiological Trends of Fungemia in Greece with a Focus on Candidemia during the Recent Financial Crisis: a 10-Year Survey in a Tertiary Care Academic Hospital and Review of Literature. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	35
30	Oral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against Enterobacterales : the Importance of Heteroresistance for Growth Outcome. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	13
31	Comparative pharmacokinetics of the three echinocandins in ICU patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2969-2976.	3.0	7
32	Manogepix (APX001A) <i>In Vitro</i> Activity against <i>Candida auris</i> : Head-to-Head Comparison of EUCAST and CLSI MICs. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	30
33	Interleukin-6 Blocking vs. JAK-STAT Inhibition for Prevention of Lung Injury in Patients with COVID-19. <i>Infectious Diseases and Therapy</i> , 2020, 9, 707-713.	4.0	18
34	Population pharmacokinetics of micafungin over repeated doses in critically ill patients: a need for a loading dose?. <i>Journal of Pharmacy and Pharmacology</i> , 2020, 72, 1750-1760.	2.4	4
35	Re: In the name of common sense: EUCAST breakpoints and potential pitfalls. National dissemination of EUCAST guidelines is a shared responsibility. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1692-1693.	6.0	8
36	Nationwide surveillance of azole-resistant <i>Aspergillus fumigatus</i> environmental isolates in Greece: detection of pan-azole resistance associated with the TR46/Y121F/T289A cyp51A mutation. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3181-3188.	3.0	12

#	ARTICLE	IF	CITATIONS
37	Exploring the Interplay of Resistance Nodulation Division Efflux Pumps, <i>Amp^C</i> and <i>OprD</i> in Antimicrobial Resistance of <i>Burkholderia cepacia</i> Complex in Clinical Isolates. <i>Microbial Drug Resistance</i> , 2020, 26, 1144-1152.	2.0	6
38	Efficacy of single and multiple oral doses of fosfomycin against <i>Pseudomonas aeruginosa</i> urinary tract infections in a dynamic in vitro bladder infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1879-1888.	3.0	9
39	Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for <i>Candida albicans</i> Using a Validated In Vitro Pharmacokinetic/Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	4
40	Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic <i>In Vitro</i> Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	19
41	Revision of EUCAST breakpoints: consequences for susceptibility of contemporary Danish mould isolates to isavuconazole and comparators. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2573-2581.	3.0	3
42	Comparison of MIC Test Strip and Sensititre YeastOne with the CLSI and EUCAST Broth Microdilution Reference Methods for <i>In Vitro</i> Antifungal Susceptibility Testing of <i>Cryptococcus neoformans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	11
43	Evaluation of pooled human urine and synthetic alternatives in a dynamic bladder infection in vitro model simulating oral fosfomycin therapy. <i>Journal of Microbiological Methods</i> , 2020, 171, 105861.	1.6	15
44	A multicentre study to optimize echinocandin susceptibility testing of <i>Aspergillus</i> species with the EUCAST methodology and a broth microdilution colorimetric method. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1799-1806.	3.0	10
45	Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1807-1819.	3.0	37
46	Bacterial quantification in tissue homogenates from in vivo pharmacodynamic studies using growth curves. <i>Journal of Medical Microbiology</i> , 2020, 69, 676-684.	1.8	2
47	Development and multicentre validation of an agar-based screening method for echinocandin susceptibility testing of <i>Aspergillus</i> species. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2247-2254.	3.0	8
48	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e405-e421.	9.1	970
49	Voriconazole efficacy against <i>Candida glabrata</i> and <i>Candida krusei</i> : preclinical data using a validated in vitro pharmacokinetic/pharmacodynamic model. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 75, 140-148.	3.0	4
50	Variation of MIC measurements: the contribution of strain and laboratory variability to measurement precision—authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1761-1762.	3.0	7
51	<i>In Vitro</i> and <i>In Vivo</i> Exposure-Effect Relationship of Liposomal Amphotericin B against <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	7
52	Experimental <i>Candida albicans</i> osteomyelitis: Microbiologic, antigenic, histologic, and 18FDG-PET-CT imaging characteristics in a newly established rabbit model. <i>Medical Mycology</i> , 2019, 57, 1011-1017.	0.7	7
53	An alternative strategy for combination therapy: Interactions between polymyxin B and non-antibiotics. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 34-39.	2.5	37
54	Triple combination of meropenem, colistin and tigecycline was bactericidal in a dynamic model despite mere additive interactions in checkerboard assays against carbapenemase-producing <i>Klebsiella pneumoniae</i> isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 387-394.	3.0	15

#	ARTICLE	IF	CITATIONS
55	How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in <i>Aspergillus fumigatus</i> isolates using four-well azole-containing agar plates. <i>Clinical Microbiology and Infection</i> , 2019, 25, 681-687.	6.0	59
56	Oral Ribavirin with or without the Addition of Immune Globulin for the Treatment of Lower Respiratory Tract Infections Due to Respiratory Syncytial Virus or Parainfluenza in Patients after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 4498-4498.	1.4	0
57	A New Marker of Echinocandin Activity in an <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic Model Correlates with an Animal Model of <i>Aspergillus fumigatus</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	1
58	Exploring colistin pharmacodynamics against <i>Klebsiella pneumoniae</i> : a need to revise current susceptibility breakpoints. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 953-961.	3.0	21
59	Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an in vitro dynamic bladder infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 709-719.	3.0	30
60	Multicentre determination of rezafungin (CD101) susceptibility of <i>Candida</i> species by the EUCAST method. <i>Clinical Microbiology and Infection</i> , 2018, 24, 1200-1204.	6.0	30
61	Variation of MIC measurements: the contribution of strain and laboratory variability to measurement precision. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2374-2379.	3.0	65
62	Azole-Resistance in <i>Aspergillus terreus</i> and Related Species: An Emerging Problem or a Rare Phenomenon?. <i>Frontiers in Microbiology</i> , 2018, 9, 516.	3.5	66
63	Management of Invasive Fungal Infections in Adult Patients with Hematological Malignancies in Greece during the Financial Crisis: Challenges and Recommendations. <i>Journal of Fungi (Basel)</i> Tj ETQq1 1 0.784314.1.gBT /Overlock 10	1.4	0
64	<i>In Vitro</i> Antifungal Susceptibility Testing of <i>Candida</i> Isolates with the EUCAST Methodology, a New Method for ECOFF Determination. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	30
65	A prospective international <i>Aspergillus terreus</i> survey: an EFISC, ISHAM and ECMM joint study. <i>Clinical Microbiology and Infection</i> , 2017, 23, 776.e1-776.e5.	6.0	42
66	Comparison of EUCAST and CLSI Reference Microdilution MICs of Eight Antifungal Compounds for <i>Candida auris</i> and Associated Tentative Epidemiological Cutoff Values. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	189
67	Comparative Evaluation of Sensititre YeastOne and CLSI M38-A2 Reference Method for Antifungal Susceptibility Testing of <i>Aspergillus</i> spp. against Echinocandins. <i>Journal of Clinical Microbiology</i> , 2017, 55, 1714-1719.	3.9	23
68	OUP accepted manuscript. <i>Medical Mycology</i> , 2017, 55, 859-868.	0.7	19
69	Pharmacodynamics of nitrofurantoin at different pH levels against pathogens involved in urinary tract infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3366-3373.	3.0	18
70	Multicentre validation of 4-well azole agar plates as a screening method for detection of clinically relevant azole-resistant <i>Aspergillus fumigatus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3325-3333.	3.0	39
71	Pharmacodynamics of fosfomycin against ESBL- and/or carbapenemase-producing Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3374-3381.	3.0	25
72	Amplification of Antimicrobial Resistance in Gut Flora of Patients Treated with Ceftriaxone. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	18

#	ARTICLE	IF	CITATIONS
73	Fluconazole Pharmacokinetics in <i>Galleria mellonella</i> Larvae and Performance Evaluation of a Bioassay Compared to Liquid Chromatography-Tandem Mass Spectrometry for Hemolymph Specimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	20
74	Spectrophotometric reading of EUCAST antifungal susceptibility testing of <i>Aspergillus fumigatus</i> . <i>Clinical Microbiology and Infection</i> , 2017, 23, 98-103.	6.0	18
75	Comparative Evaluation of Etest, EUCAST, and CLSI Methods for Amphotericin B, Voriconazole, and Posaconazole against Clinically Relevant <i>Fusarium</i> Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	21
76	Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and <i>Klebsiella pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 172-180.	3.0	6
77	Balanced control of both hyper and hypo-inflammatory phases as a new treatment paradigm in sepsis. <i>Journal of Thoracic Disease</i> , 2016, 8, E312-E316.	1.4	18
78	Comparison of Short Versus Prolonged Infusion of Standard Dose of Meropenem Against Carbapenemase-Producing <i>Klebsiella pneumoniae</i> Isolates in Different Patient Groups: A Pharmacokinetic–Pharmacodynamic Approach. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 1513-1518.	3.3	16
79	Successful therapy of <i>Candida pulcherrima</i> fungemia in a premature newborn with liposomal amphotericin B and micafungin. <i>Medical Mycology Case Reports</i> , 2016, 12, 24-27.	1.3	4
80	Reply to “Agar Bioassays for Antifungals in Combination Therapy”. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5626-5626.	3.2	0
81	Intra- and Interlaboratory Agreement in Assessing the In Vitro Activity of Micafungin against Common and Rare <i>Candida</i> Species with the EUCAST, CLSI, and Etest Methods. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6173-6178.	3.2	15
82	Dose optimization of voriconazole/anidulafungin combination against <i>Aspergillus fumigatus</i> using an in vitro pharmacokinetic/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3135-3147.	3.0	18
83	Pharmacodynamics and differential activity of nitrofurantoin against ESBL-positive pathogens involved in urinary tract infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2883-2889.	3.0	23
84	Clofazimine Prevents the Regrowth of <i>Mycobacterium abscessus</i> and <i>Mycobacterium avium</i> Type Strains Exposed to Amikacin and Clarithromycin. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1097-1105.	3.2	85
85	In vitro combinations of natamycin with voriconazole, itraconazole and micafungin against clinical <i>Fusarium</i> strains causing keratitis: Table 1. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 953-955.	3.0	53
86	EUCAST technical note on isavuconazole breakpoints for <i>Aspergillus</i> , itraconazole breakpoints for <i>Candida</i> and updates for the antifungal susceptibility testing method documents. <i>Clinical Microbiology and Infection</i> , 2016, 22, 571.e1-571.e4.	6.0	104
87	Bioassay for Determining Voriconazole Serum Levels in Patients Receiving Combination Therapy with Echinocandins. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 632-636.	3.2	13
88	Pharmacokinetic–pharmacodynamic modelling of meropenem against VIM-producing <i>Klebsiella pneumoniae</i> isolates: clinical implications. <i>Journal of Medical Microbiology</i> , 2016, 65, 211-218.	1.8	11
89	Evaluation of paper gradient concentration strips for antifungal combination testing of <i>Candida</i> spp.. <i>Mycoses</i> , 2015, 58, 679-687.	4.0	3
90	In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the <i>Mucorales</i> Order. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7735-7742.	3.2	89

#	ARTICLE	IF	CITATIONS
91	The Strength of Synergistic Interaction between Posaconazole and Caspofungin Depends on the Underlying Azole Resistance Mechanism of <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1738-1744.	3.2	25
92	Treatment of Experimental <i>Candida</i> Sepsis with a Janus Kinase Inhibitor Controls Inflammation and Prolongs Survival. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7367-7373.	3.2	17
93	Synergistic interactions between colistin and meropenem against extensively drug-resistant and pandrug-resistant <i>Acinetobacter baumannii</i> isolated from ICU patients. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 670-671.	2.5	15
94	Optimization of Polyene-Azole Combination Therapy against Aspergillosis Using an <i>In Vitro</i> Pharmacokinetic-Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3973-3983.	3.2	18
95	Prospective Multicenter International Surveillance of Azole Resistance in <i>Aspergillus fumigatus</i> . <i>Emerging Infectious Diseases</i> , 2015, 21, 1041-1044.	4.3	302
96	<i>In Vitro</i> and <i>In Vivo</i> study on the effect of antifungal agents on hematopoietic cells in mice. <i>Experimental Biology and Medicine</i> , 2015, 240, 1728-1734.	2.4	0
97	Evaluation of the "Dip Effect" Phenomenon in Antifungal Susceptibility Testing of <i>Candida</i> spp. against Echinocandins by Use of Gradient Concentration Strips. <i>Journal of Clinical Microbiology</i> , 2015, 53, 3654-3659.	3.9	5
98	<i>In vitro</i> interactions between farnesol and fluconazole, amphotericin B or micafungin against <i>Candida albicans</i> biofilms. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 470-478.	3.0	96
99	Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and <i>Aspergillus fumigatus</i> in an <i>in vitro</i> pharmacokinetic/pharmacodynamic model—authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 634-635.	3.0	4
100	Fungal malignant otitis externa caused by <i>Alternaria chlamydospora</i> : first case report. <i>JMM Case Reports</i> , 2015, 2, .	1.3	3
101	<i>Rhodotorula mucilaginosa</i> associated meningitis: A subacute entity with high mortality. Case report and review. <i>Medical Mycology Case Reports</i> , 2014, 6, 46-50.	1.3	14
102	Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and <i>Aspergillus fumigatus</i> in an <i>in vitro</i> pharmacokinetic/pharmacodynamic model. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1611-1619.	3.0	28
103	ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: <i>Fusarium</i> spp., <i>Scedosporium</i> spp. and others. <i>Clinical Microbiology and Infection</i> , 2014, 20, 27-46.	6.0	383
104	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. <i>Clinical Microbiology and Infection</i> , 2014, 20, 47-75.	6.0	262
105	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. <i>Clinical Microbiology and Infection</i> , 2014, 20, 5-26.	6.0	547
106	Susceptibility Breakpoints for Amphotericin B and <i>Aspergillus</i> Species in an <i>In Vitro</i> Pharmacokinetic-Pharmacodynamic Model Simulating Free-Drug Concentrations in Human Serum. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2356-2362.	3.2	16
107	EUCAST Testing of Isavuconazole Susceptibility in <i>Aspergillus</i> : Comparison of Results for Inoculum Standardization Using Conidium Counting versus Optical Density. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6432-6436.	3.2	12
108	<i>In Vitro</i> Combination of Isavuconazole with Micafungin or Amphotericin B Deoxycholate against Medically Important Molds. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6934-6937.	3.2	39

#	ARTICLE	IF	CITATIONS
109	Rare Invasive Fungal Infections: Epidemiology, Diagnosis and Management. <i>Current Fungal Infection Reports</i> , 2013, 7, 351-360.	2.6	26
110	Inhibitory and Fungicidal Effects of Antifungal Drugs against <i>Aspergillus</i> Species in the Presence of Serum. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1625-1631.	3.2	21
111	<i>In Vitro</i> Interaction of Voriconazole and Anidulafungin against Triazole-Resistant <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 796-803.	3.2	35
112	Single-Dose Pharmacodynamics of Amphotericin B against <i>Aspergillus</i> Species in an <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3713-3718.	3.2	10
113	Amphotericin B- and Voriconazole-Echinocandin Combinations against <i>Aspergillus</i> spp.: Effect of Serum on Inhibitory and Fungicidal Interactions. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4656-4663.	3.2	32
114	Near-Infrared Spectroscopy of the Urinary Bladder during Voiding in Men with Lower Urinary Tract Symptoms: A Preliminary Study. <i>BioMed Research International</i> , 2013, 2013, 1-7.	1.9	10
115	Composite Survival Index to Compare Virulence Changes in Azole-Resistant <i>Aspergillus fumigatus</i> Clinical Isolates. <i>PLoS ONE</i> , 2013, 8, e72280.	2.5	20
116	Epidemiological Cutoff Values for Azoles and <i>Aspergillus fumigatus</i> Based on a Novel Mathematical Approach Incorporating <i>cyp51A</i> Sequence Analysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2524-2529.	3.2	36
117	Pharmacodynamic Effects of Simulated Standard Doses of Antifungal Drugs against <i>Aspergillus</i> Species in a New <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 403-410.	3.2	38
118	Molecular detection and identification of enteroviruses in children admitted to a university hospital in Greece. <i>Molecular and Cellular Probes</i> , 2011, 25, 249-254.	2.1	18
119	Comparative Evaluation of Three Commercial Identification Systems Using Common and Rare Bloodstream Yeast Isolates. <i>Journal of Clinical Microbiology</i> , 2011, 49, 2722-2727.	3.9	41
120	Synergistic Interaction of the Triple Combination of Amphotericin B, Ciprofloxacin, and Polymorphonuclear Neutrophils against <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5923-5929.	3.2	8
121	Comparative pharmacodynamic interaction analysis of triple combinations of caspofungin and voriconazole or ravuconazole with subinhibitory concentrations of amphotericin B against <i>Aspergillus</i> spp.. <i>Mycoses</i> , 2010, 53, 239-245.	4.0	14
122	Defining Fractional Inhibitory Concentration Index Cutoffs for Additive Interactions Based on Self-Drug Additive Combinations, Monte Carlo Simulation Analysis, and <i>In Vitro</i> - <i>In Vivo</i> Correlation Data for Antifungal Drug Combinations against <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 602-609.	3.2	250
123	Combination Therapy in Treatment of Experimental Pulmonary Aspergillosis: <i>In Vitro</i> and <i>In Vivo</i> Correlations of the Concentration- and Dose- Dependent Interactions between Anidulafungin and Voriconazole by Bliss Independence Drug Interaction Analysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2382-2391.	3.2	90
124	<i>In vitro</i> activity of CAY-1, a saponin from <i>Capsicum frutescens</i> , against <i>Microsporidium</i> and <i>Trichophyton</i> species. <i>Medical Mycology</i> , 2008, 46, 805-810.	0.7	12
125	Infections Caused by <i>Scedosporium</i> spp. <i>Clinical Microbiology Reviews</i> , 2008, 21, 157-197.	13.6	640
126	Isobolographic Analysis of Pharmacodynamic Interactions between Antifungal Agents and Ciprofloxacin against <i>Candida albicans</i> and <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2196-2204.	3.2	31

#	ARTICLE	IF	CITATIONS
127	Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against <i>Candida albicans</i> and <i>Aspergillus fumigatus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 63, 343-348.	3.0	46
128	Comparative In Vitro Pharmacodynamics of Caspofungin, Micafungin, and Anidulafungin against Germinated and Nongerminated <i>Aspergillus Conidia</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 321-328.	3.2	73
129	Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents. <i>Pharmacogenomics</i> , 2008, 9, 561-584.	1.3	31
130	Host-Dependent Patterns of Tissue Injury in Invasive Pulmonary Aspergillosis. <i>American Journal of Clinical Pathology</i> , 2007, 127, 349-355.	0.7	137
131	Differential Fungicidal Activities of Amphotericin B and Voriconazole against <i>Aspergillus</i> Species Determined by Microbroth Methodology. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3329-3337.	3.2	85
132	Study of common functional genetic polymorphisms of <i>FCGR2A</i> , <i>3A</i> and <i>3B</i> genes and the risk for cryptococcosis in HIV-uninfected patients. <i>Medical Mycology</i> , 2007, 45, 513-518.	0.7	34
133	Concentration-Dependent Effects of Caspofungin on the Metabolic Activity of <i>Aspergillus</i> Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 881-887.	3.2	49
134	Concentration-Dependent Synergy and Antagonism within a Triple Antifungal Drug Combination against <i>Aspergillus</i> Species: Analysis by a New Response Surface Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2053-2064.	3.2	57
135	Relationship between metabolism and biomass of medically important zygomycetes. <i>Medical Mycology</i> , 2006, 44, 429-438.	0.7	9
136	The concentration-dependent nature of in vitro amphotericin B–itraconazole interaction against <i>Aspergillus fumigatus</i> : isobolographic and response surface analysis of complex pharmacodynamic interactions. <i>International Journal of Antimicrobial Agents</i> , 2006, 28, 439-449.	2.5	28
137	Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against <i>Aspergillus</i> species. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 1168-1176.	3.0	51
138	Use of Quantitative Real-Time PCR To Study the Kinetics of Extracellular DNA Released from <i>Candida albicans</i> , with Implications for Diagnosis of Invasive Candidiasis. <i>Journal of Clinical Microbiology</i> , 2006, 44, 143-150.	3.9	53
139	Triazole–Polyene Antagonism in Experimental Invasive Pulmonary Aspergillosis: In Vitro and In Vivo Correlation. <i>Journal of Infectious Diseases</i> , 2006, 194, 1008-1018.	4.0	99
140	Human Pharmacogenomic Variations and Their Implications for Antifungal Efficacy. <i>Clinical Microbiology Reviews</i> , 2006, 19, 763-787.	13.6	35
141	Rapid Susceptibility Testing of Medically Important Zygomycetes by XTT Assay. <i>Journal of Clinical Microbiology</i> , 2006, 44, 553-560.	3.9	49
142	Use of high inoculum for early metabolic signalling and rapid susceptibility testing of <i>Aspergillus</i> species. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 59, 230-237.	3.0	25
143	Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. <i>Medical Mycology</i> , 2005, 43, 133-152.	0.7	99
144	Susceptibility testing of sequential isolates of <i>Aspergillus fumigatus</i> recovered from treated patients. <i>Journal of Medical Microbiology</i> , 2004, 53, 129-134.	1.8	39

#	ARTICLE	IF	CITATIONS
145	In Vitro Drug Interaction Modeling of Combinations of Azoles with Terbinafine against Clinical <i>Scedosporium prolificans</i> Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 106-117.	3.2	234
146	Use of Turbidimetric Growth Curves for Early Determination of Antifungal Drug Resistance of Filamentous Fungi. <i>Journal of Clinical Microbiology</i> , 2003, 41, 4718-4725.	3.9	39
147	In vitro susceptibilities of zygomycetes to conventional and new antifungals. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 45-52.	3.0	299
148	Comparison of the Etest and the Sensititre Colorimetric Methods with the NCCLS Proposed Standard for Antifungal Susceptibility Testing of <i>Aspergillus</i> Species. <i>Journal of Clinical Microbiology</i> , 2002, 40, 2876-2885.	3.9	59
149	In Vitro Activities of New and Conventional Antifungal Agents against Clinical <i>Scedosporium</i> Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 62-68.	3.2	230
150	Methodological issues related to antifungal drug interaction modelling for filamentous fungi. <i>Reviews in Medical Microbiology</i> , 2002, 13, 101-117.	0.9	13
151	Comparison of Spectrophotometric and Visual Readings of NCCLS Method and Evaluation of a Colorimetric Method Based on Reduction of a Soluble Tetrazolium Salt, 2,3-Bis {2-Methoxy-4-Nitro-5-[(Sulfenylamino) Carbonyl]-2H- Tetrazolium-Hydroxide}, for Antifungal Susceptibility Testing of <i>Aspergillus</i> Species. <i>Journal of Clinical Microbiology</i> , 2001, 39, 4256-4263.	3.9	71
152	Colorimetric Assay for Antifungal Susceptibility Testing of <i>Aspergillus</i> Species. <i>Journal of Clinical Microbiology</i> , 2001, 39, 3402-3408.	3.9	148
153	In Vitro Interaction of Terbinafine with Itraconazole against Clinical Isolates of <i>Scedosporium prolificans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 470-472.	3.2	105
154	Comparison of NCCLS and 3-(4,5-Dimethyl-2-Thiazyl)-2,5-Diphenyl-2H-Tetrazolium Bromide (MTT) Methods of In Vitro Susceptibility Testing of Filamentous Fungi and Development of a New Simplified Method. <i>Journal of Clinical Microbiology</i> , 2000, 38, 2949-2954.	3.9	203